GET DAILY SIGNALSCytomX Therapeutics (CTMX) Shares Decline -14% Over 30 Days: Factors Behind the Move
Key Takeaways
- CytomX Therapeutics shares fell roughly 14% over the last 30 days, sliding from about $2.69 (September 28) to $2.31 (October 27) as post-offering dilution overhang and speculative-biotech selling pressure persisted.
- The move extends a longer downtrend: the stock is down about 28% over the last quarter and roughly 46% year to date, within a 52-week range of $2.20 to $8.21.
- No single company-specific negative catalyst triggered the decline; it instead reflects a Q2 2026 revenue miss, heavy short interest near 23% of float, and rising Treasury yields pressuring risk assets.
- CytomX's lead candidate, Varseta-M (CX-2051), continues to show encouraging activity in late-line colorectal cancer, with confirmed response rates of 20%–32%, and a registrational study is targeted for the first half of 2027.
- The company held $346.7 million in cash, cash equivalents and investments as of March 31, 2026, supporting a projected runway into the second half of 2028.
- Wall Street consensus remains constructive despite the decline, with average price targets near $12 versus a share price around $2.31.
- For more detail on this ticker, explore CytomX's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how AI-driven trading strategies are positioning across the market.
CytomX Therapeutics (CTMX) Business Overview
CytomX Therapeutics, Inc. (CTMX) is a clinical-stage biopharmaceutical company based in South San Francisco that focuses on oncology. Its PROBODY platform applies molecular masking to produce conditionally activated biologics. These remain inactive in healthy tissue and activate mainly in the tumor microenvironment, which can improve the safety profile for antibody-drug conjugates, T-cell engagers, and immune modulators.
The lead program is Varseta-M (varsetatug masetecan; CX-2051), a masked EpCAM-directed topoisomerase-1 inhibitor ADC aimed at metastatic colorectal cancer. A second program, CX-801, is a masked interferon alpha-2b cytokine under study for metastatic melanoma. The company maintains partnerships with Amgen (AMGN), Bristol Myers Squibb (BMY), Regeneron (REGN), and Moderna (MRNA). Clinical updates and partnership progress remain central to investor attention.
CTMX Stock Performance Over the Past 30 Days and Quarter
Over the last 30 days, CTMX fell approximately 14%, moving from a close of $2.69 on September 28, 2026, to $2.31 on October 27, 2026. Selling occurred steadily rather than in one sharp session, and the shares touched a new 52-week intraday low of $2.18 on October 26. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The recent drop fits into a wider quarterly decline. On July 28, 2026, the stock closed near $3.22, for a roughly 28% fall over the quarter. Over the past year the shares have ranged between $2.20 and $8.21, reflecting an early-2026 rally on positive Varseta-M data followed by pressure from dilution and revenue trends.
Drivers of the Recent 30-Day Decline
No single company announcement sparked the latest move. A second-quarter revenue shortfall continued to weigh on sentiment after the company posted $1.42 million versus expectations near $12.4 million, as collaboration revenue from completed programs with Bristol Myers Squibb and Astellas tapered off. Short interest remained elevated at about 40.8 million shares, or roughly 23% of the float as of late September. Higher Treasury yields and reduced appetite for speculative small-cap biotech names added further pressure.
Analyst target adjustments were mixed. J.P. Morgan lowered its target from $12 to $11 and Guggenheim moved from $15 to $14, while Cantor Fitzgerald kept an Overweight rating and $12 target on October 13, and Piper Sandler reiterated $12 in late September. The result was a gradual decline rather than an abrupt break.
Quarterly Performance Context and Balance Sheet
The quarterly trend follows the unwind of an earlier rally. CTMX reached a 52-week high of $8.21 in the first quarter of 2026 after Phase 1 data showed Varseta-M delivering a 32% confirmed response rate at the 10 mg/kg dose in late-line colorectal cancer. A $250 million public offering at $5.30 per share in March, a discount of about 21% to the prior close, increased the share count and weighed on the price.
Since then, collaboration revenue has declined while operating expenses have risen to support Varseta-M manufacturing. The company’s cash position of $346.7 million as of March 31, 2026, extends the runway into the second half of 2028, which has offered some support even as investors await the next clinical catalysts.
Near-Term Catalysts and What to Monitor
Several upcoming events could influence the stock. The company expects a Phase 1 safety and efficacy update for Varseta-M in the second half of 2026, including progression-free survival data from dose-optimization cohorts and an initial overall-survival look. This update is intended to support FDA alignment on a registrational trial design. A pivotal study in late-line colorectal cancer is targeted to start in the first half of 2027, and initial data for CX-801 combined with pembrolizumab in advanced melanoma is anticipated around year-end 2026.
Investors will also watch FDA feedback on the registrational path, potential expansion into other EpCAM-expressing tumors, and cash usage relative to development plans. Macro factors such as interest rates and risk appetite for pre-revenue biotech, along with the stock’s short interest, remain relevant. Binary clinical or regulatory outcomes carry meaningful risk for any company at this stage.
Exploring AI Tools for Market Analysis
I have found Tickeron’s AI Trading Bots useful when reviewing how systematic strategies are responding to current conditions in the biotech sector. The platform offers a range of automated approaches that can help surface patterns across many tickers without replacing individual due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CTMX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CTMX turned positive on October 20, 2026. Looking at past instances where CTMX's MACD turned positive, the stock continued to rise in 36 of 43 cases over the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CTMX's RSI Oscillator exited the oversold zone, 35 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 64 cases where CTMX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
Following a +10.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where CTMX advanced for three days, in 185 of 238 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
CTMX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CTMX as a result. In 73 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTMX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CTMX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.666) is normal, around the industry mean (3.037). P/E Ratio (-4.053) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (27.624) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. CTMX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTMX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer
Industry Biotechnology
Advertisement